Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q7LFX5

UPID:
CHSTF_HUMAN

ALTERNATIVE NAMES:
B-cell RAG-associated gene protein; N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase

ALTERNATIVE UPACC:
Q7LFX5; O60338; O60474; Q86VM4

BACKGROUND:
The enzyme Carbohydrate sulfotransferase 15, recognized for its alternative name B-cell RAG-associated gene protein, is integral to the formation of chondroitin sulfate E. It uniquely transfers sulfate to non-reducing terminal sequences, contributing to the sulfation pattern critical for biological functions. Additionally, it may play a role in B-cell development and regulation, although its in vivo effects require further clarification.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Carbohydrate sulfotransferase 15 offers a promising avenue for drug discovery. Its dual role in glycosaminoglycan biosynthesis and potential involvement in B-cell regulation highlights its significance in therapeutic development.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.